Ankylosing spondylitis
Conference Coverage
High multimorbidity in axial spondyloarthritis
BIRMINGHAM, ENGLAND – Many patients with axial spondyloarthritis have other medical conditions, such as depression and fibromyalgia, which may...
Conference Coverage
Low-dose CT has a place in spondyloarthritis imaging toolbox
MADISON, WISC. – Low-dose CT of the sacroiliac joints is in the same minimal risk category as a chest radiograph.
From the Journals
Active psoriatic arthritis, ankylosing spondylitis linked to increase in adverse pregnancy outcomes
Women with psoriatic arthritis and ankylosing spondylitis generally have favorable pregnancy outcomes, but high disease activity during pregnancy...
Conference Coverage
VA system lags in getting DMARDs to veterans with inflammatory arthritis
MADISON, WISC. – More than two-thirds of ankylosing spondylitis patients didn’t receive a DMARD in the first year...
Conference Coverage
Ankylosing spondylitis patients taking COX-2 inhibitors may see fewer cardiovascular events
MADISON, WISC. – Meta-analysis of studies has limitations but provides “reassuring” data for rheumatologists caring...
Conference Coverage
Experts agree on optimal use of MRI in axSpA
BIRMINGHAM, ENGLAND – Expert recommendations give guidance on how to standardize the use of MRI to diagnose axial spondyloarthritis.
Latest News
Mobile SpA apps abound, but there’s room for quality improvement
MADISON, WISC. – Smartphone app quality was higher when health care providers had input in app development.
From the Journals
Smoking found not protective against uveitis attacks in axSpA patients
In contrast to previous reports, an analysis of registry data finds that smoking is not protective against acute anterior uveitis episodes.
News from the FDA/CDC
FDA approves new etanercept biosimilar, Eticovo
Eticovo (etanercept-ykro) is the second FDA-approved etanercept biosimilar after Erelzi (etanercept-szzs).
Feature
Referral system aims to slash axial spondyloarthritis diagnostic delay
News from the FDA/CDC
Cimzia becomes first FDA-approved treatment for nonradiographic axial spondyloarthritis
Approval was based on the results of 52 weeks of double-blind therapy versus placebo.